



ANALYTICA LTD - ABN 12 006 464 866

## **ASX ANNOUNCEMENT**

## Results of 2018 Annual General Meeting

## **22 November 2018**

Analytica Limited (ASX:ALT) advises that all resolutions were passed by a show of hands.

Proxy votes received were as follows:

| Resolution<br>Number | Resolution<br>Name                      | For<br>resolution | Open votes<br>held by the<br>Chair (for<br>resolution) | Against resolution | Abstain from voting |
|----------------------|---|-------------------|--|--------------------|---------------------|
| 1                    | Adoption of the                         | 521,333,523       | 68,758,070   | 14,305,802         | 27,313,263          |
|                      | Remuneration Report                     | 86.26%            | 11.38%   | 2.37%              |                     |
| 2                    | Re-election of Dr Michael               | 985,029,881       | 71,727,618   | 10,140,585         | 796,591,275         |
|                      | Monsour as a Director                   | 92.33%            | 6.72%  | 0.95%              |                     |
| 3                    | Re-election of Dr Thomas                | 1,755,680,430     | 70,966,734   | 12,673,766         | 24,168,429          |
|                      | Lönngren as a Director                  | 95.45%            | 3.86%  | 0.69%              |                     |
| 4                    | Approval of Enhanced                    | 1,756,680,430     | 70,839,728   | 35,979,672         | 300,200             |
|                      | Placement Capacity - Special Resolution | 94.27%            | 3.80%  | 1.93%              |                     |

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:









## **About Analytica Limited**

Analytica's lead product is the PeriCoach<sup>®</sup> System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale from pericoach.com in Australia, New Zealand, UK and Ireland.